Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 14/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.41 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | CTSA | P10619 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20556534 | 1.00 | ADORA2A (0.46) | ADORA2APIK3CDPIK3R2GRM5CTSA | |
| SCHEMBL17769161 | 0.78 | ADORA2A (0.48) | ADORA2APIK3CDGRM5 | |
| SCHEMBL20556354 | 0.75 | CTSA (0.44) | GRM5CTSA | |
| SCHEMBL17768613 | 0.75 | CTSA (0.44) | GRM5CTSA | |
| SCHEMBL21555725 | 0.73 | TACR3 (0.48) | GRM5CTSA | |
| SCHEMBL20556613 | 0.73 | CTSA (0.53) | ADORA2AGRM5CTSA | |
| SCHEMBL20556556 | 0.73 | CTSA (0.53) | ADORA2AGRM5CTSA | |
| SCHEMBL17768736 | 0.73 | CTSA (0.53) | ADORA2AGRM5CTSA | |
| SCHEMBL20556542 | 0.73 | GRM5 (0.48) | ADORA2AGRM5CTSA | |
| SCHEMBL17769165 | 0.73 | GRM5 (0.48) | ADORA2AGRM5CTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472347-B2 | Aminopyrazine compounds with A2A antagonist properties | MERCK SHARP & DOHME CORP. (US) | 2019-11-12 | — | — | US | claimed |
| US-20180327385-A1 | AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2018-11-15 | — | — | US | claimed |
| US-10472347-B2 | Aminopyrazine compounds with A2A antagonist properties | MERCK SHARP & DOHME CORP. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472347-B2 | Aminopyrazine compounds with A2A antagonist properties | MERCK SHARP & DOHME CORP. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20180327385-A1 | AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2018-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472347-B2 | Aminopyrazine compounds with A2A antagonist properties | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885PIK3CD 2974/4885PIK3R2 2148/4885 |
| US-20180327385-A1 | AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885PIK3CD 2974/4885PIK3R2 2148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.